Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 407-560-9 | CAS number: 107934-68-9 CAF
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 7 May - 1 Jun 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Also in accordance with GLP principles.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Version / remarks:
- adopted 19. Sept. 1984
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Test was done before LLNA as first-choice method for in-vivo testing was set into force.
Test material
- Reference substance name:
- 4,4'-(9H-fluoren-9-ylidene)bis(2-chloroaniline)
- EC Number:
- 407-560-9
- EC Name:
- 4,4'-(9H-fluoren-9-ylidene)bis(2-chloroaniline)
- Cas Number:
- 107934-68-9
- Molecular formula:
- C25H18Cl2N2
- IUPAC Name:
- 4-[9-(4-amino-3-chlorophenyl)-9H-fluoren-9-yl]-2-chloroaniline
- Test material form:
- solid: particulate/powder
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: D. Hall, Newchurch, Staffordshire, England
- Age at study initiation: 6 to 7 weeks of age
- Weight at study initiation: 327 - 389 g
- Housing: in groups of ten in suspended cages with wire mesh floors
- Diet: vitamin C-enriched guinea pig diet F.D.1., ad libitum; hay was given weekly
- Water: ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21
- Humidity (%): 30-70
- Air changes (per hr): approximately 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 7 May To 01 June 1991
Study design: in vivo (non-LLNA)
Induction
- Route:
- intradermal and epicutaneous
- Vehicle:
- other: Alembicol D
- Concentration / amount:
- Induction: intradermal - 2.5% w/w; epicutaneous - 70% w/w
Challenge: epicutaneous - 25 and 50% w/w
Challenge
- Route:
- epicutaneous, semiocclusive
- Vehicle:
- other: Alembicol D
- Concentration / amount:
- Induction: intradermal - 2.5% w/w; epicutaneous - 70% w/w
Challenge: epicutaneous - 25 and 50% w/w
- No. of animals per dose:
- 10 (controls), 20 (in test group)
- Details on study design:
- RANGE FINDING TESTS: The intradermal and topical irritancy of a range of dilutions of T-4113 was investigated to identify where possible (a) irritant test concentrations suitable for induction phase of the main study and (b) non-irritant concentrations by the topical route of administration for the challenge phase. Concentration ranges tested in two animals each were: intradermal - 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 7.5, 10.0% (w/w); topical - 10, 30, 50, 70% (w/w)
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intradermal and epicutaneous, respectively)
- Exposure period: single intradermal injection and 48 hours topical application
- Test groups:
Intradermal - 3 pairs of injections: (1) a 1:1 mixture (v/v) Freund's Complete adjuvant (FCA)/water; (2) test substance in Alembicol D; (3) test substance in a 1:1 mixture of Freund's complete adjuvant and Alembicol D
Epicutaneous - test substance in Alembicol D
- Control group:
Intradermal - 3 pairs of injections: (1) a 1:1 mixture (v/v) FCA/water; (2) Alembicol D; (3) 1:1 mixture Freund's Complete adjuvant and Alembicol D
Epicutaneous - Alembicol D
- Site: scapular region, intradermal and epicutaneous
- Frequency of applications: every 7 days
- Duration: Days 0-9
- Concentrations: intradermal 2.5% w/w, epicutaneous 70% w/w
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 21
- Exposure period: 24 hours
- Test groups: test substance at 25 and 50% w/w in Alembicol D
- Control group: test substance at 25 and 50% w/w in Alembicol D
- Site: anterior and posterior site on the left flank
- Concentrations: 25 and 50% w/w
- Evaluation (hr after challenge): 24, 48 and 72 hours
OTHER:
Justification for choice of vehicle: Alembicol D# is a product of coconut oil. By fractionating the fatty acids of coconut oil and re-esterifying with glycerine, a Medium Chain Triglyceride (MCT) Oil is produced. Alembicol D is such an oil. It is advantageous in this type of test in that it is stable, has a low viscosity and surface tension and is easily absorbed into the skin. These properties make it ideal as a vehicle for intradermal injections and topical applications. - Positive control substance(s):
- yes
- Remarks:
- Formalin (checked periodically)
Results and discussion
- Positive control results:
- Formalin is used as positive control and checked regularly to test the stability of the assay;
concentrations used: intradermal - 0.05 -0.1%; epicutaneous - 5 -10%; challenge - 1 -5%; usually 50 - 100% of the tested animals showed sensitizing reactions in all studies conducted
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- other: 3rd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- other: 3rd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 1st reading
- Group:
- positive control
- Dose level:
- Challenge 5% and 1%
- No. with + reactions:
- 10
- Total no. in group:
- 10
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- In this adjuvant type guinea pig test method for skin sensitisation according to OECD 406 guideline and GLP principles, the substance did not produce evidence of skin sensitization in any of the twenty test animals.
- Executive summary:
Assessment of the skin sensitization potential of the test substance using the guinea-pig according to OECD 406 guideline and GLP principles. No signs of ill health or toxicity were recorded.
Induction:
Intradermal injections: Necrosis was recorded at sites receiving FCA in test and control animals. Slight irritation was seen in test animals at sites receiving the 2.5% test substance in Alembicol D and similar signs of irritation were observed in control animals receiving Alembicol D.
Topical application: Slight erythema was observed in test animals following topical application with the 70% test substance in Alembicol D and similar signs of irritation were seen in the controls.
Challenge:
There were no dermal reaction seen in any of the test or control animals.
Based on the results, the substance did not produce evidence of skin sensitization in any of the twenty test animals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
